The aim of this review is to highlight the association between type 2 diabetes mellitus (DM) and cognitive impairment/Alzheimer’s disease (AD) and provide an updated summary of the evidence related to various potentially modifiable risk factors such as hyperinsulinaemia,insulin resistance,hypo-and hyperglycaemia, vascular risk factors like hypertension and obesity, micro and macrovascular complications, depression in AD.Treating modifiable risk factors can reduce the prevalence of AD.In addition we provide the information about potential benefits of antidiabetic agents for slowing of cognitive decline and AD in patients with type2 DM. There were studies demonstrating the novel effects of antidiabetic agents on neuronal functions by increased insulin signaling in an AD brain with a neuroprotective and neurotrophic effect. In this regard insulin, metformin and thiazolidinediones (in particular, rosiglitazone and pioglitazone ) would have potential protective effect for the development of AD.
| Published in | Science Journal of Clinical Medicine (Volume 2, Issue 3) |
| DOI | 10.11648/j.sjcm.20130203.20 |
| Page(s) | 114-121 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2013. Published by Science Publishing Group |
Alzheimer’s Disease, Anti-Diabetic Medication, Dementia, Type 2 Diabetes
| [1] | Ferri CP, Prince M, Brayne C, et al. Alzheimer’s Disease International. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366:2112–7. |
| [2] | Alzheimer’s Association. 2010 Alzheimer’s disease facts and figures. Alzheimers Dement 2010; 6: 158–94. |
| [3] | E Duron and Olivier Hanon. Vascular risk factors, cognitve decline, and dementia. Vasc Health Risk Manag. 2008 April; 4 (2): 363–381. |
| [4] | Allen KV, Frier BM, Strachan MW. The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. Eur J Pharmacol. 2004;490:169–75. |
| [5] | Curb JD, Rodriguez BL, Abbott RD, et al. Longitudinal association of vascular and Alzheimer’s dementias, diabetes, and glucose tolerance. Neurology. 1999;52:971–5. |
| [6] | Peila R, Rodriguez BL, Launer LJ., Honolulu-Asia Aging Study Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes. 2002;51:1256–62. |
| [7] | Yamada M, Kasagi F, Sasaki H, et al. Association between dementia and midlife risk factors: the Radiation Effects Research Foundation Adult Health Study. J Am Geriatr Soc. 2003;51:410–4. |
| [8] | Schnaider Beeri M, Goldbourt U, Silverman JM, et al. Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology. 2004;63:1902–7. |
| [9] | Biessels GJ, Staekenborg S, Brunner E, et al. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006;5:64–74. |
| [10] | Yael D. Reijmer, Esther van den Berg, Carla Ruis. Cognitive dysfunction in patients with type 2 diabetes. Diabetes Metab Res Rev 2010; 26: 507–519. |
| [11] | Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001; 154:635–641. |
| [12] | Solfrizzi V, Panza F, Colacicco AM, et al. Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology 2004; 63: 1882–1891. |
| [13] | T. Cukierman, H. C. Gerstein and J. D. Williamson.Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies.2005, Volume 48, Number 12, Pages 2460-2469. |
| [14] | Yos. itake T, Kiyohara Y, Kato I, et al. Incidence and risk factors of vascular dementia and Alzheimer’s. Disease in a defined elderly Japanese population: the Hisayama Study. Neurology1995; 45: 1161–1168 |
| [15] | Ott A, Stolk RP, van Harskamp F, Pols HA,et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999; 53: 1937–1942. |
| [16] | Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 2002; 51: 1256–1262. |
| [17] | XuWL, Qiu CX, Wahlin A, Winblad B, Fratiglioni L. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 2004; 63: 1181–1186. XuWL, |
| [18] | Thomas J, Steven T, et al. Clinical manifestations and diagnosis of Alzheimer disease: J Neurology and psychiatry; September 2010. |
| [19] | Kua EH. The prevalence of dementia in elderly Chinese. Acta Psychiatr Scand 1991: 83: 350-352. |
| [20] | E. Rönnemaa, B. Zethelius, J. Sundelöf, et al.Glucose metabolism aZetheliussk of Alzheimer’s disease and dementia: a population-based 12 year follow-up study in 71-year-old men: 2009, Volume 52. Number 8, Pages 15 |
| [21] | Neumann KF, Rojo L, Navarrete LP, et al. Insulin resistance and Alzheimer’s disease: molecular links and clinical implications. Curr Alzheimer Res 2008 (5): 438–447. |
| [22] | De Felice FG, Vieira MN, Bomfim TR et al .Protection of synapses against Alzheimer’s-linked toxins: Insulin signalling prevents the pathogenic binding of A (beta) oligomers. Proc Natl Acad Sci U S A 10:1971–1976. |
| [23] | Araki A. Dementia and insulin resistance in patients with diabetes mellitus. Nihon Rinsho.2010 Mar; 68 (3): 569-74. |
| [24] | Hsueh, W. Genetic discoveries as the basis of personalized therapy: rosiglitazone treatment of Alzheimer's disease : The Pharmacogenomics Journal6. 4 (Jul 2006): 222-4. |
| [25] | Pasquier F , Boulogne A , Leys D , Fontaine P. Diabetes mellitus and dementia.Diabetes Metab 2006;32:403. |
| [26] | Mark W. J. Strachan, Rebecca M. Reynolds, Brian M. Frier, The relationship between type 2 diabetes and dementia.Br Med Bull (2008) 88 (1): 131-146. |
| [27] | Strachan MWJ.. Insulin and cognitive function. Lancet 2003;362. 1253 (letter). |
| [28] | Kuusisto J, Koivisto K, Mykkanen L, et al. Essential hypertension and cognitive function. The role of hyperinsulinemia. Hypertension. 1993;22:771-779. |
| [29] | Almijn S,Feskens EJM, Launer LJ, et al.Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men. Diabetologia 1995;38:1096-1102. |
| [30] | Stolk RP, Breteler MMB, Ott A, et al. Insulin and cognitive function in an elderly population. The Rotterdam study. Diabetes Care 1997;20:792-795. |
| [31] | Gold PE. Role of glucose in regulating the brain and cognition. Am J Clin Nutr 1995;61:987S-95S. |
| [32] | The Diabetes Control and Complications Trial/Epidemiology of Diabetes interventions and Complications (DCCT/EDIC) Study Research Group. Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. New England Journal of Medicine; 2005 vol. 353 no. 25 |
| [33] | Kumari M, Brunner E, Fuhrer R. Minireview: mechanisms by which the metabolic syndrome and diabetes impair memory. J Gerontol A Biol Sci Med Sci. 2000;5: B228–32. |
| [34] | Xu WL, Qiu CX, Wahlin A, Winblad B, Fratiglioni L.Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology. 2004 Oct 12;63 (7): 1181-6. |
| [35] | Deary IJ. Symptoms of hyperglycemia and effects on mental performance and emotions. In Hypoglycaemia in Clinical Diabetes, (2nd edn), Frier BM, Fisher M (Eds). John Wiley & Sons: Chichester, 2007; 25. |
| [36] | Warren RE, Frier BM. Hypoglycemia and cognitive function. Diabetes Obes Metab 2005; 7: 493–503. |
| [37] | Bruce DG, Davis WA, Casey GP, et al. Severe hypoglycemia and cognitive impairment in older patients with diabetes: The Fremantle Diabetes Study. Diabetologia 2009; 52: 1808–1815. |
| [38] | Snowdon DA, Greiner LH,et al. Brain infarction and the clinical expression of Alzheimer’s disease. The Nun Study. J Am Med Assoc 1997;277:813-7. |
| [39] | Kloppenborg RP, van den Berg E, Kappelle LJ, Biessels GJ. Diabetes and other vascular risk factors for dementia: which factor matters most? A systematic review. Eur J Pharmacol 2008; 585: 97–108. |
| [40] | Gustafson D. A life course of adiposity and dementia. EurJ Pharmacol 2008; 585: 163–175. |
| [41] | Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141–1145. |
| [42] | Bruehl H, Wolf OT, Sweat V, Tirsi A, Richardson S, Convit A. Modifiers of cognitive function and brain structure in middle aged and elderly individuals with type 2 diabetes mellitus. Brain Res 2009; 1280: 186–194. |
| [43] | Bruce DG, Davis WA, Casey GP, et al. Predictors of cognitive impairment and dementia in older people with diabetes. Diabetologia 2008; 51: 241–248. |
| [44] | Manschot SM, Biessels GJ, de Valk HW, et al. Metabolic and vascular determinants of impaired cognitive performance and abnormalities on brain magnetic resonance imaging in patients with type 2 diabetes. Diabetologia 2007; 50: 2388–2397. |
| [45] | van den Berg E, Dekker JM, Nijpels G, et al. Blood pressure levels in pre-diabetic stages are associated with worse cognitive functioning in patients with type 2 diabetes. Diabetes MetabRes Rev 2009; 25: 657–664. |
| [46] | Goodpaster BH, Krishnaswami S, Harris TB, Katsiaras A,Kritchevsky SB, Simonsick EM,et al.Obesity, regional body fat distribution, and the metabolic syndrome in older men and women. Arch Intern Med 2005; 165: 777–83. |
| [47] | Beydoun MA, Lhotsky A,Wang Y, Dal Forno G, An Y,Metter EJ, Ferrucci L, et al. AB. An association of adiposity status and changes in early mid-adulthood with incidence of Alzheimer’s disease. Am J Epidemiol 2008; 168: 1179–89. |
| [48] | Fitzpatrick AL, Kuller LH, Lopez OL, et al. Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch Neurol 2009; 66: 336–42. |
| [49] | Dahl AK, Lopponen M, Isoaho R, Berg S, Kivela SL. Overweight and obesity in old age are not associated with greater dementia risk. J Am Geriatr Soc 2008; 56: 2261–66 |
| [50] | Knopman DS, Edland SD, Cha RH, Petersen RC, Rocca WA. Incident dementia in women is preceded by weight loss by at least a decade. Neurology 2007; 69: 739–46. |
| [51] | Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006; 5: 64–74. |
| [52] | Iehuis AM, van der Graaf Y, Visseren FL, et al . Diabetes increases atrophy and vascular lesions on brain MRI in patients with symptomatic arterial disease. Stroke 2008;39:1600-1603. |
| [53] | Ferguson SC, Blane A, Perros P, et al. Cognitive ability and brain structure in type 1 diabetes: relation to microangiopathy and preceding severe hypoglycemia. Diabetes 2003; 52:149–156. |
| [54] | Ryan CM, Geckle MO, Orchard TJ. Cognitive efficiency declines over time in adults with Type 1 diabetes: effects of micro- and macrovascular complications. Diabetologia 2003;46: 940–948. |
| [55] | Wessels AM, Rombouts SA, Remijnse PL, et al. Cognitive performance in type 1 diabetes patients is associated with the cerebral white matter volume. Diabetologia 2007; 50: 1763–1769. |
| [56] | De Luis DA, Fernandez N, Arranz M, Aller R, Izaola O. Total homocysteine and cognitive deterioration in people with type 2 diabetes. Diabetes Res Clin Pract 2002; 55: 185–190. |
| [57] | Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA2002; 287: 2570–2581. |
| [58] | van den Berg E, de Craen AJ, Biessels GJ, Gussekloo J,Westendorp RG. The impact of diabetes mellitus on cognitive decline in the oldest of the old: a prospective population-based study. Diabetologia 2006; 49: 2015–2023. |
| [59] | Umegaki H, Iimuro S, Kaneko T, et al. Factors associated with lower Mini Mental State Examination scores in elderly Japanese diabetes mellitus patients. Neurobiol Aging 2008; 29:1022–1026. |
| [60] | Brands AMA, van den Berg E, Manschot SM, et al. A detailed profile of cognitive dysfunction and its relation to psychological distress in patients with type 2 diabetes mellitus. J Int Neuropsychol Soc 2007; 13: 288–297. |
| [61] | van den Berg E, Dekker JM, Nijpels G, et al. Cognitive functioning in elderly persons with type 2 diabetes and metabolic syndrome: the Hoorn study. Dement Geriatr CognDisord 2008; 26: 261–269. |
| [62] | Kalmijn S, Feskens EJM, Launer LJ, Kromhout D. Cerebrovascular disease, the apolipoprotein ε4 allele, and cognitive decline in a community-based study of elderly men. Stroke 1996;27:2230-5. |
| [63] | HaanMN, Shemanski L, JagustWJ,et al. The role of APOE epsilon4 in modulating the effects of other risk factors for cognitive decline in elderly persons. JAMA 1999;282: 40–46. |
| [64] | Blair CK, Folsom AR, Knopman DS,et al. APOE genotype and cognitive decline in a middle-aged cohort. Neurology 2005; 64: 268–276. |
| [65] | 65Qiu WQ, Folstein MF. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer’s disease: review and hypothesis. Neurobiol Aging 2006; 27: 190–198. |
| [66] | Edland SD, Wavrant-De-Vriese F, Compton D, et al. Insulin degrading enzyme (IDE) genetic variants and risk of Alzheimer’s disease: evidence of effect modification by apolipoprotein E (APOE). Neurosci Lett 2003; 345: 21–24. |
| [67] | Edland SD. Insulin-degrading enzyme, apolipoprotein E, and Alzheimer’s disease. J Mol Neurosci 2004; 23: 213–217. |
| [68] | Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001; 24: 1069–1078. |
| [69] | Krabbe KS, Nielsen AR, Krogh-Madsen R, et al. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia2007; 50: 431–438. |
| [70] | Baldwin RC, O’Brien J. Vascular basis of late-onset depressive disorder. Br J Psychiatry 2002; 180: 157–160. |
| [71] | Bruce DG, Casey G, Davis WA, et al. Vascular depression in older people with diabetes. Diabetologia 2006; 49: 2828–2836 |
| [72] | Knol MJ, Twisk JWR, Beekman ATF, et al. Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia 2006; 49:837–845 |
| [73] | Schmidt R, Schmidt H, Curb JD, Masaki K, et al. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002; 52: 168–74. |
| [74] | Engelhart MJ, Geerlings MI,Meijer J, Kiliaan A,et al. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch Neurol 2004; 61: 668–72. |
| [75] | Hak AE, Pols HA, Stehouwer CD, Meijer J, et al. Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam study. J Clin Endocrinol Metab 2001; 86: 4398–405. |
| [76] | Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 2003; 27 (Suppl. 3): S53–5. |
| [77] | Columbia University, Institute for the Study of Aging, National Institute on Aging. Metformin in amnestic mild cognitive impairment (MCI). Available at top: //clinical trials. Gov/ct2/show/NCT00620191 (last accessed 19 August 2010). |
| [78] | Killick R, Scales G, Leroy K, Causevic M, et al. Deletion of Irs2 reduces amyloid deposition and rescues behavioral deficits in APP transgenic mice. Biochem Biophys Res Comm 2009; 386: 257–62. |
| [79] | Paromita King, Ian Peacock, Richard Donnelly.The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol. 1999 November; 48 (5): 643–648. |
| [80] | UK Prospective Diabetes Study Group.Quality of life in type 2 diabetic patient patients is affected by complications but ot by intensive policies to improve blood glucose or blood pressure control.Diabetes care 1999;22(7):1125-36. |
| [81] | A. P. Kengne, A. Patel, S. Colagiuri, S. Heller and P. Hamet, et al.The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular event. in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) Study.2010, Volume 53, Number 5, Pages 821-831. |
| [82] | Williamson JD, Miller ME, Bryan RN, Lazar RM, Coker LH, Johnson J, Cukierman T.ect. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. ACCORD Study Group:Am J Cardiol. 2007 Jun 18;99 (12A): 112i-122i. |
| [83] | Takashi Sakurai, MD, PhD. Targets of the Peroxisome Proliferator–Activated Receptor _ Agonist Trials for the Prevention of Alzheimer Disease: Arch neurol/VOL 68 (NO. 4), APR 2011; Pg 542 |
| [84] | Luis Escribano, Ana-María Simón, Alberto Pérez-Mediavilla, Pablo Salazar-Colocho, Joaquín Del Río,Diana Frechilla. Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer’s disease mouse model: Biochemical and Biophysical Research Communications 379 (2009) 406–410 |
| [85] | C. Harrington, S. Sawchak, C. Chiang, J. Davies, C. Donovan, A.M. Saunders, et al. Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimer's Disease: Two Phase 3 Studies: Current Alzheimer Research, 2011, 8, 592-606 |
| [86] | Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR,Asthana S,et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 2005; 13:950–8 |
| [87] | Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging in press |
| [88] | Hanyu H, Sato T, Kiuchi A, Sakurai H, Iwamoto T. Pioglitazone improved cognition in a pilot study in patients with Alzheimer’s disease and mild cognitive impairment with diabetes mellitus. J Am Geriatr Soc 2009;57: 177–9 |
| [89] | Massimiliano Plastino , Antonietta Fava , Domenico Pirritano , Piero Cotronei , Natalina Sacco , Teresa Sperlì ,et al.Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and Diabetes Mellitus type-2; Journal of the Neurological Sciences 288 (2010) 112–116 |
| [90] | Suzanne Craft, PhD; Laura D. Baker, PhD; Thomas J. Montine, MD, PhD; Satoshi Minoshima, MD,et al.Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment.: A Pilot Clinical Trial ;Author Affiliations: Geriatric Research, Education, and Clinical Center (Drs Craft, Baker, Watson, Claxton, Callaghan, and Plymate and Mr Arbuckle) and Mental Illness Research, Education, and Clinical Center (Drs Leverenz and Gerton), Veterans Affairs Puget Sound Health Care System, and Departments of Psychiatry and Behavioral Sciences (Drs Craft, Baker, Watson, Claxton, and Leverenz), Pathology (Dr Montine), Radiology (Drs Minoshima and Cross), Medicine (Drs Tsai, Plymate, and Green), and Neurology (Drs Leverenz and Gerton), University of Washington School of Medicine, Seattle, Arch Neurol. 2012;69(1):29-38. |
| [91] | Helgi B Schiöth, William H Frey .Insulin to Treat Alzheimer's Disease: Expert Rev Clin Pharmacol. 2012;5(1):17-20. © 2012 Expert Reviews Ltd. |
| [92] | Chih-Cheng Hsua, Mark L. Wahlqvista,, Meei-Shyuan Leec and Hsin-Ni Tsaia. Incidence of Dementia is Increased in Type 2 Diabetes and Reduced by the Use of Sulfonylureas and Metformin. Journal of Alzheimer’s Disease 24 (2011) 485–493. |
| [93] | Grzybowska M, Bober J, Olszewska M. Metformin - mechanisms of action and use for the treatment of type 2 diabetes mellitus]. Postepy Hig Med Dosw (Online). 2011 May 6;65:277-85. |
| [94] | Luchsinger JA. Type 2 diabetes, related conditions, in relation and dementia: an opportunity for prevention? J Alzheimers Dis. 2010;20(3):723-36. Review. |
| [95] | Stephen F.J, McGovern, Kerry Hunter, Christian Hölscher.Effects of the glucagon-like polypeptide-1 analogue (Val8)GLP-1 on learning, progenitor cell proliferation and neurogenesis in the C57B/16 mouse brain.BrainResearch,2012;1473:204 |
APA Style
Aye Aye Myint, Kyaw Soe Win, Zaw Aung. (2013). Alzheimer’s Disease and Type 2 Diabetes Mellitus: Risk Factors and Effectiveness of Antidiabetic Agents in Treatment of Alzheimer’s Disease. Science Journal of Clinical Medicine, 2(3), 114-121. https://doi.org/10.11648/j.sjcm.20130203.20
ACS Style
Aye Aye Myint; Kyaw Soe Win; Zaw Aung. Alzheimer’s Disease and Type 2 Diabetes Mellitus: Risk Factors and Effectiveness of Antidiabetic Agents in Treatment of Alzheimer’s Disease. Sci. J. Clin. Med. 2013, 2(3), 114-121. doi: 10.11648/j.sjcm.20130203.20
AMA Style
Aye Aye Myint, Kyaw Soe Win, Zaw Aung. Alzheimer’s Disease and Type 2 Diabetes Mellitus: Risk Factors and Effectiveness of Antidiabetic Agents in Treatment of Alzheimer’s Disease. Sci J Clin Med. 2013;2(3):114-121. doi: 10.11648/j.sjcm.20130203.20
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.sjcm.20130203.20,
author = {Aye Aye Myint and Kyaw Soe Win and Zaw Aung},
title = {Alzheimer’s Disease and Type 2 Diabetes Mellitus: Risk Factors and Effectiveness of Antidiabetic Agents in Treatment of Alzheimer’s Disease},
journal = {Science Journal of Clinical Medicine},
volume = {2},
number = {3},
pages = {114-121},
doi = {10.11648/j.sjcm.20130203.20},
url = {https://doi.org/10.11648/j.sjcm.20130203.20},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sjcm.20130203.20},
abstract = {The aim of this review is to highlight the association between type 2 diabetes mellitus (DM) and cognitive impairment/Alzheimer’s disease (AD) and provide an updated summary of the evidence related to various potentially modifiable risk factors such as hyperinsulinaemia,insulin resistance,hypo-and hyperglycaemia, vascular risk factors like hypertension and obesity, micro and macrovascular complications, depression in AD.Treating modifiable risk factors can reduce the prevalence of AD.In addition we provide the information about potential benefits of antidiabetic agents for slowing of cognitive decline and AD in patients with type2 DM. There were studies demonstrating the novel effects of antidiabetic agents on neuronal functions by increased insulin signaling in an AD brain with a neuroprotective and neurotrophic effect. In this regard insulin, metformin and thiazolidinediones (in particular, rosiglitazone and pioglitazone ) would have potential protective effect for the development of AD.},
year = {2013}
}
TY - JOUR T1 - Alzheimer’s Disease and Type 2 Diabetes Mellitus: Risk Factors and Effectiveness of Antidiabetic Agents in Treatment of Alzheimer’s Disease AU - Aye Aye Myint AU - Kyaw Soe Win AU - Zaw Aung Y1 - 2013/06/30 PY - 2013 N1 - https://doi.org/10.11648/j.sjcm.20130203.20 DO - 10.11648/j.sjcm.20130203.20 T2 - Science Journal of Clinical Medicine JF - Science Journal of Clinical Medicine JO - Science Journal of Clinical Medicine SP - 114 EP - 121 PB - Science Publishing Group SN - 2327-2732 UR - https://doi.org/10.11648/j.sjcm.20130203.20 AB - The aim of this review is to highlight the association between type 2 diabetes mellitus (DM) and cognitive impairment/Alzheimer’s disease (AD) and provide an updated summary of the evidence related to various potentially modifiable risk factors such as hyperinsulinaemia,insulin resistance,hypo-and hyperglycaemia, vascular risk factors like hypertension and obesity, micro and macrovascular complications, depression in AD.Treating modifiable risk factors can reduce the prevalence of AD.In addition we provide the information about potential benefits of antidiabetic agents for slowing of cognitive decline and AD in patients with type2 DM. There were studies demonstrating the novel effects of antidiabetic agents on neuronal functions by increased insulin signaling in an AD brain with a neuroprotective and neurotrophic effect. In this regard insulin, metformin and thiazolidinediones (in particular, rosiglitazone and pioglitazone ) would have potential protective effect for the development of AD. VL - 2 IS - 3 ER -
Email: